Recent Advances in Nanosponges as Drug Delivery System



  • Uday B Bolmal
  • F V Manvi
  • Rajkumar Kotha
  • Sai Sowjanya Palla
  • Anusha Paladugu
  • Korivi Ramamohan Reddy


Major problem of many newly developed chemical entities is their poor solubility in water and pharmacokinetic issues. These poorly-water soluble drugs show many problems in formulating them in conventional dosage forms and the critical problem associated is its very low bio-availability. Nanotechnology has attracted increasing attention during recent years and it can resolve the problems associated with solubility and bio-availability. Nanosponges are a part of nanotechnology. Nanosponges delivery system, which was originally developed for topical delivery of drugs, can also be used for controlled oral delivery of drugs using water soluble and bioerodible polymers. Nanosponges are tiny sponges with a size of about a virus, which can be filled with wide variety of drugs. These tiny sponges can circulate around the body until they encounter the specific target site and stick on the surface and begin to release the drug in a controlled and predictable manner. Because the drug can be released at the specific target site instead of circulating throughout the body it will be more effective for specific disease targeted treatment. Another important character of these sponges is their aqueous solubility; this allows the use of these systems effectively for drugs with poor solubility. 


Download data is not yet available.


Metrics Loading ...


Nanosponges, Topical drug delivery, Controlled release, Poor solubility, Biodegradable polymers




How to Cite

Bolmal UB, Manvi FV, Kotha R, Palla SS, Paladugu A, Reddy KR. Recent Advances in Nanosponges as Drug Delivery System. Scopus Indexed [Internet]. 2013 May 31 [cited 2024 Feb. 25];6(1):1934-4. Available from:



Review Articles


Aithal KS, Udupa N and Sreenivassan KK (1995). Physicochemical properties of drug-cyclodextrin complexes. Indian Drugs 32: 293-305.

Amber V, Shailendra S and Swarnalatha S (2008). Cyclodextrin based novel drug delivery systems. J InclPhenomMacrocyclChem 62: 23-42.

Andrea M, Franca C, Luciana M, Fabio G, Giuseppina R, Francesco T, Barbara R, Aldo Fand Giovanni G (2011). HR MAS NMR, powder XRD andraman spectroscopy study of inclusion phenomena 111 in βCD nanosponges. J InclPhenomMacrocyclChem 69: 403-409.

Ansari KA, Torne SJ, Vavia PR, Trotta Fand Cavalli R (2011). Paclitaxel loaded nanosponges: in-vitro characterization and cytotoxicity study on MCF-7 cell line culture. Curr Drug Deliv 8: 194- 202.

Arkas M, Allabashi R, Tsiourvas D, Mattausch EM and Perfler R (2006). Organic/inorganic hybrid filters based on dendritic and cyclodextrin "nanosponges" for the removal of organic pollutants from water. Environ SciTechnol 40: 2771-2777.

Arun R, Ashokkumar CK and Sravanthi VVNSS (2008). Cyclodextrins as drug carrier Molecule: A Review. Sci Pharm 76: 567-598

Bekers O, Uijtendaal E.V, Beijnen J.H, Bult A and W.J.M (1991).. Underberg.Cyclodextrinsinthe pharmaceutical field. Drug Dev. Ind. Pharm. 17: 1503-1549.

Cavalli R, Trotta F and Tumitti V (2006). Cyclodextrin based nanosponges for drug delivery. J. Inclphenommacrocyl chem. 56: 209-13.

Cavalli R, Akhter AK, Bisazza A, Giustetto P, Trotta F and Vavia P (2010). Nanosponge formulations as oxygen delivery systems.Int J Pharm 402: 254-257.

David F. Nanosponge drug delivery system more effective than direct 01.06.2010, accessed on 20.12.2011.

DeQuan L and Min M (2000). Nanosponges for water purification. Clean products and processes 2: 112-116.

Di Nardo G, Roggero C, Campolongo S, Valetti F, Trotta F and Gilardi G (2009). Catalytic properties of catechol 1,2-dioxygenase from Acinetobacterradioresistens S13 immobilized on nanosponges. Dalton Trans 33: 6507-6512.

Duchene D, Vaution C and Glomot F (1998). Cyclodextrin, Their Value in pharmaceutical Technology. Drug DevInd Pharm 12: 2193-2215.

Duchene D, VautionC and Glomot F (1988).Cyclodextrin, Their Value in pharmaceutical Technology. Drug Dev. Ind. Pharm 12: 2193-2215.

Edward C and David A. Tanner (2010). Characterisation of Porous Silicon NanospongeParticles. Department of Manufacturing and Operations Engineering and Materials and Surface Science Institute, University of Limerick, Ireland.

Erden N and Celebi N (1988). A study of the inclusion complex of Naproxen with β- cyclodextrin. Int. J. Pharm. 48: 83-89.

Eva Harth (2011). Nanomedicine: Development of “Nanosponges” as superior sustain delivery systems of diverse biological cargos. Department of Chemistry, Vanderbilt University, USA.

Fouda MMG, KnitellD,HiplerU.C,Elsner P and Schollmey E (1995). Antimycotic influence of β-cyclodextrin complexes—In vitro measurements using laser nephelometry in microtiter plates. Int. J. Pharm. 311: 113-121.

Glomot F, BenkerrourL,Duchene D and M.C (1988). Poelman.Improvement in availability and stability of a dermocorticoid by inclusion in β-cyclodextrin. Int. J. Pharm. 46: 49- 55.

Gu H, Zheng R., Liu H, Zhang X and Xu B (2005). Direct Synthesis of a Bimodal Nanosponge Based on FePt and ZnS. Small 2005;1: 402–406. DOI: 10.1002/smll.200400106.

Isabelle A, Christine V, Helene C, Elias F and Patrick C (1999). Spongelike Alginate Nanoparticles as a new potential system for the delivery of Antisense Oligonucleotides. Antisense and Nucleic Acid Drug Development 9: 301-312.

Jadhav GS and Vavia PR (2008)..Physicochemical, in silico and in vivo evaluation of a Danazol– β-cyclodextrin complex. Int. J. Pharm. 352: 5-1696(8): 2018-2028(2007).

Jenny A, Merima P, Alberto F and Francesco T (2011). Role of β- cyclodextrinnanosponges in polypropylene photooxidation. Carbohydrate Polymers 86: 127– 135.

Khalid AA, Pradeep RV, Francesco T and Roberta C (2011). Cyclodextrin-based nanosponges for delivery of Resveratrol: In Vitro characterisation, stability, cytotoxicity and permeation Study AAPS. PharmSciTech 12: 279-286.

Khopade AJ, Jain S and Jain NK (1996). “The Microsponge”. Eastern Pharmacist;49-53.

Lala R, Thorat A and Gargote C (2011). Current trends in β- cyclodextrin based drug delivery systems. Int J Res Ayur Pharm 2: 1520-1526.

Leslie Z. Benet. BCS and BDDCS (2007). Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability. Department of biopharmaceutical sciences, University of California, San Francisco, USA.

Liang L, De-Pei L and Chih-Chuan L (2002). Optimizing the delivery systems of chimeric RNA . DNA oligonucleotides beyond general oligonucleotide transfer. Eur. J. Biochem 269: 5753–5758.

Longo C, Gambara G, Espina V, LuchiniA,Bishop B, Patanarut AS, Petricoin EF 3rd, Beretti F, Ferrari B, Garaci E, De Pol A, Pellacani G and Liotta LA (2011;). A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. ExpDermatol. 20: 29-34.

Nilesh J, Ruchi J, Navneet T, Brham P, Gupta, Deepak K, Jeetendra B and Surendra J (2010). Nanotechnology: A Safe And Effective Drug Delivery System. Asian J Phar Cli Res 3: 159-165.

Noriaki F, Seiji I and Saburo N (2008). Advances in physical chemistry and pharmaceutical applications of cyclodextrins. Pure ApplChem 80: 1511-1524.

Marzouqi A.H.A, Shehatta I, Jobe B and Dowaidar A (2006). Phase solubility and inclusion complex of Itraconazole with ß-cyclodextrin using supercritical carbon dioxide. J Pharm Sci 95: 292-304.

Patel E. K and Oswal R.J (2012).Nanosponge and Microsponges: A Novel Drug Delivery System.IJRP 2 ISSN: 2231-2781

Patel G and Patel JK (2008).Use of a Microsponge in Drug Delivery Systems.Pharmaceutical processing 158.

Rajeswari C, Alka A, Javed A and Khar R K (2005). Cyclodextrins in drug delivery: an update review. AAPS pharmSciTech 6: E329-E357.

Ramnik S, Nitin B, Jyotsana M and Horemat SN (2010). Characterization of Cyclodextrin Inclusion complexes –A Review. J Pharm SciTech 2: 171-183.

Renuka S and Kamla P (2011). Polymeric nanosponges as an alternative carrier for improved retention of econazole nitrate onto the skin through topicalhydrogel formulation. Pharm DevTechnol 16: 367-376.

Renuka S, Roderick BW and Kamla P (2011). Evaluation of the kinetics and mechanism of drug release from Econazole Nitrate nanosponge loaded carbapol hydrogel. Ind J ParmEduRes 45: 25-31.

RiBeiroL.S.S, FalcaoA.C, Patricio J.A.B, Ferreira D.C and Veiga F.J.B (2007). Cyclodextrin multicomponent complexation and controlledrelease delivery strategies to optimize the oral bioavailability of Vinpocetine. J. Pharm. Sci. 6: 2018-28.

Rosalba M, Roberta C, Roberto F, Chiara D, Piergiorgio P, Leigh E, Li S and Roberto P (2011). Antitumor activity of nanosponge-encapsulated Camptotechin in human prostate tumors. Cancer Res 71: 4431.

SelvamuthukumarS,SingireddyA,Krishnamoorthy K and Rajappan M (2012). Nanosponges: A Novel Class of Drug Delivery System – Review. J Pharm PharmaceutSci 15(1): 103 - 111,

Shankar S, Linda P, Loredana S, Francesco T, Pradeep V, Dino A, Michele T, Gianpaolo Z and Roberta C (2010). Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm 74: 193-201.

Shankar S, Vavia PR, Francesco T and Satyen T (2007;). Formulation of Betacyclodextrin based nanosponges of Itraconazole. J InclPhenomMacrocyclChem 57: 89–94.

Sharma R, Roderick B and Pathak K (2011). Evaluation of kinetics and mechanism of drug release from Econazole nitrate Nanosponges loaded carbopol Hydrogel. Indian JofPharmaEdu and research 45: 25-31.

Sinha V.R, Anitha R, Ghosh S, Nanda A and Kumria R (2005). Complexation of Celecoxib with ß-cyclodextrin: Characterization of the interaction in solution and in solid state. J. Pharm. Sci. 94: 676-687

Swaminathan S, Cavalli R, Trotta F and Vavia PR (2007). Formulation of betacyclodextrin based nanosponges of itraconazole. J. Incl. Phemon. Macrocycl.Chem 57: 89-94.

Swaminathan S, Cavalli R, Trotta F and Vavia PR (2010). In vitro release modulation and conformational stabilization of a model protein using swellablepolyamidoaminenanosponges of cyclodextrin. J.Incl.Phemon.Macrocycl.ChemDOI 10.1007/s10847-010-9765-9.

Swaminathan S, Pastero L, Serpe L, Trotta F and Vavia P ( 2010). Cyclodextrinbasednanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity. Eup J of Pharmaceutics and Biopharmaceutics 74: 193-201.

Swaminathan S, Vavia P, Trotta F and Torne S (2007). Formulation of beta cyclodextrin based nanosponges of Itraconazole. J. Incl.Phemon.Macrocyl.chem 57: 89-94

Tayade PT and Vavia PP (2006). Inclusion complexes of Ketoprofen with β- cyclodextrins: Oral pharmacokinetics of Ketoprofen in human. Indian J Pharm Sci 68: 164-170.

Tayade P.T. and Vavia P.R (2006). Inclusion complexes of Ketoprofen with β- cyclodextrins: Oral pharmacokinetics of Ketoprofen in human. Indian J. Pharm. Sci. 68: 164-170

Torne SJ, Ansari KA, Vavia PR, Trotta F and Cavalli R ( 2010). Enhanced oral Paclitaxel bioavailability after administration of Paclitaxel loaded nanosponges. Drug Delivery 17: 419–425.

Trotta, F, Cavalli, R, Vavia PR and Khalid A (2011). Cyclodextrin nanosponges as effective gas carriers. J of Inclusion Phenomena and Macrocyclic Chemistry, online first TM, 22nd Feb. DOI: 10.1007/s10847-011-9926-5.

Trotta F, Cavalli R, Tumiatti W, Zerbinati O, Rogero C and Vallero R (2007). Ultrasound-assisted synthesis of Cyclodextrin-based nanosponges. EP1 786 841 B1

Trotta F, Tumiatti V, Cavalli R, Rogero C, Mognetti B and Berta G(2009). Cyclodextrin-based nanosponges as a vehicle for Antitumoral drugs. WO 2009/003656 A1.

Trotta F and Tumiatti W (2003). Cross linked polymers based on cyclodextrin for removing polluting agents.; WO 03/085002.

Trotta F and Cavalli R (2009). Characterization and applications of new hyper-crosslinkedcyclode-xtrins. Composite interfaces 16: 39-48.

UekamaK,HirayamaF,Otagiri M andYamasaki M (1982). Inclusion complexations of steroid hormones with cyclodextrins in water and in solid phase. Int. J. Pharm. 10: 1-15.

Uekama K, Fujinaga T, Hirayama F, OtagiriM,Yamasali M, SeoH,Hasimoto T and TsuruokaT(1983). Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation. J. Pharm. Sci.72(11): 1338-1341.

Vavia P, Swaminathan S, Trotta Fand Cavalli R (2006). Applications of nanosponges in drug delivery. XIII International Cyclodextrins symposium Turin 14-17.

WangL,Jiang X, XuW and Li C (2007). Complexation of Tanshinone IIA with 2- hydroxypropyl-β-cyclodextrin: Effect on aqueous solubility, dissolution rate, and intestinal absorption behavior in rats. Int. J. Pharm. 341: 58-67.

William K, Benjamin S and Eva H (2011). Synthesis and Characterization of Nanosponges for Drug Delivery and Cancer Treatment. accessed on 20.12.2011.

Wolfgang S (2007). Sample preparation in Light Scattering from Polymer Solutions and Nanoparticle Dispersions. Springer Berlin Heidelberg GmbH & Co. K. P 43-4.

Wong VN, Fernando G, Wagner AR, Zhang J, Kinsel GR, Zauscher S and Dyer DJ (2009). Separation of peptides with polyionicnanosponges for MALDIMS analysis.Langmuir 25: 1459-65.